Urokinase-type plasminogen activator deficiency enhances CD8+ T cell infiltration and anti-PD-1 therapy efficacy in prostate cancer
uPA is a significant immunosuppressive regulator in prostate cancer. Its inhibition enhances CD8⁺ T cell function and synergizes with immune checkpoint blockade, supporting uPA targeting as a novel strategy to improve prostate cancer immunotherapy efficacy.
Authors
- Yi Lü (ORCID: https://orcid.org/0000-0002-1060-6925)
- Yuhao Cui (ORCID: https://orcid.org/0009-0007-3644-7321)
- Chao‐Nan Qian (ORCID: https://orcid.org/0000-0002-1232-3419)
- Xin Huang (ORCID: https://orcid.org/0009-0003-9888-5950)
- Xinyu Ye (ORCID: https://orcid.org/0000-0001-6536-4348)
- Xing Fu (ORCID: https://orcid.org/0000-0002-8374-072X)
- Xiaoyi Li (ORCID: https://orcid.org/0000-0002-1453-4359)
- Jian Zhang (ORCID: https://orcid.org/0000-0001-6791-8949)
- Xiao Zhang (ORCID: https://orcid.org/0000-0003-1267-2034)
- Hong Wu
Institutions
- Sun Yat-sen University (CN)
- Southern University of Science and Technology (CN)
- First People's Hospital of Foshan (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangzhou Eighth People's Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1625226
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China